glp-1 with medicaid Rhode Island considers ending coverage of drugs for weight loss • Rhode Island Current More states consider dropping GLP-1

Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K, Trautmann M

Semaglutide 2.4 mg (Wegovy) has demonstrated cardiovascular benefits in the SELECT trial, though this benefit should not be assumed for all medications in this class

True Stories Of Transformation There are many stories about people who have used retatrutide peptide for weight loss

The most common reported side effects are gastrointestinal, especially nausea, diarrhea, constipation, and vomiting

The applications of GLP-1RAs extend far beyond diabetes management

RAND reports that 12% of Americans have used GLP-1s for weight loss and another 14% are interested, with prescriptions more than tripling since 2020